NCT03148366View on ClinicalTrials.gov

Comparison of the Levofloxacin Sequential Therapy and Quadruple Therapy in Second Line Treatment for HP

PHASE3CompletedINTERVENTIONAL
Enrollment

560

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2020

Conditions
Helicobacter
Interventions
DRUG

Levofloxacin based sequential therapy

D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days

DRUG

bismuth quadruple therapy for 10 days (BQ)

D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days

Trial Locations (2)

Unknown

National Taiwan University Hospital, Taipei

National Taiwan University Hospital, Yunlin branch, Yunlin

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT03148366 - Comparison of the Levofloxacin Sequential Therapy and Quadruple Therapy in Second Line Treatment for HP | Biotech Hunter | Biotech Hunter